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Abstract
Background: Although there are many methods available for measuring compliance, there is no
formal gold standard. Different techniques used to measure compliance were compared among
children treated by the anti-malarial amodiaquine/sulphadoxine-pyrimethamine (AQ/SP)
combination therapy, in use in Senegal between 2004 and 2006.
Methods: The study was carried out in 2004, in five health centres located in the Thies region
(Senegal). Children who had AQ/SP prescribed for three and one day respectively at the health
centre were recruited. The day following the theoretical last intake of AQ, venous blood, and urine
samples were collected for anti-malarial drugs dosage. Caregivers and children above five years
were interviewed concerning children's drug intake.
Results: Among the children, 64.7% adhered to 80% of the prescribed dose and only 37.7% were
strict full adherent to the prescription. There was 72.7% agreement between self-reported data and
blood drug dosage for amodiaquine treatment. Concerning SP, results found that blood dosages
were 91.4% concordant with urine tests and 90% with self-reported data based on questionnaires.
Conclusion: Self-reported data could provide useful quantitative information on drug intake and
administration. Under strict methodological conditions this method, easy to implement, can be
used to describe patients' behaviors and their use of new anti-malarial treatment. Self-reported
data is a major tool for assessing compliance in resource poor countries. Blood and urine drug
dosages provide qualitative results that confirm any drug intake. Urine assays for SP could be useful
to obtain public health data, for example on chemoprophylaxis among pregnant women.
Background
In the fight against malaria, the emergence of resistance to
chloroquine, but also to other drugs, such as mefloquine
or sulphadoxine-pyrimethamine, directs our attention to
one of the factors of resistance emergence, i.e. drug use
[1]. The theoretical effectiveness of a growing number of
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medical interventions appears to be hindered by patients'
and caregivers' behaviors concerning compliance with
treatment regimens [2,3]. In order to improve therapeutic
strategies, a particular interest is focused on the measure-
ment of compliance with treatment.
This is a complex issue since there is no benchmark [4,5].
The selection of available methods--drug assays, biologi-
cal markers, questionnaires, patient interview, drug pack-
age counts--depends upon the study's target and
organizational constraints [4]. Some researchers give pri-
ority to biological or clinical measurement to benchmark
compliance. They contend that self-reported data can be
affected by different biases--recall bias and good-will bias,
since the patient tends to give the expected answer [6,7].
Nevertheless, the questionnaire is the most common
method for measuring compliance in developing coun-
tries; its advantage is to have only a few logistic con-
straints, particularly compared to biological and blood
dosages, and to be less invasive [4]. A literature review
conducted within the malaria context pointed out the
need to combine different methods in order to validate
self-reported data--for measurement of compliance -- by
biological means [8]. Nearly all malaria-endemic coun-
tries have seen an unprecedented change in national drugs
policies in recent years. In line with WHO recommenda-
tions, they gave up chloroquine, which was becoming
ineffective and promoted artemisin-based combination
therapy as first-line treatment for mild malaria. Senegal
changed its malaria treatment in 2004, from chloroquine
to the amodiaquine/sulphadoxine-pyrimethamine (AQ/
SP) combination before the implementation of artemisi-
nin combination therapy (ACT) in 2006. The introduc-
tion of this combination therapy can be considered as a
test before the implementation of ACT in terms of health
staff behavior and public compliance with new drugs and
drug combinations. At that time in Senegal, they were not
provided in a single blister. These new combinations used
two different drugs--AQ and SP--requiring different "dos-
age regimens", for three and one day respectively. This
treatment regimen may have been difficult for the popu-
lation to understand and thus have reduced compliance.
In a study on the measurement of compliance with these
new treatments and their effectiveness, three techniques
were used: self-reporting based on questionnaires, meas-
urement of drug concentration in urine and in blood.
Results were compared and the reliability, advantages,
and disadvantages of each technique were assessed.
Methods
Study area
The study was conducted in five health facilities located in
rural areas of the health districts of Mbour and Thies, 70
km southeast of Dakar. Malaria is endemic in the study
area with seasonal outbreaks. The annual rainy season is
short (from July to October). Malaria transmission is
mainly restricted from August to November. The study
took place from September to November 2004, less than
a year after the implementation of combination AQ/SP in
Senegal.
Study design
During the study period, nurses identified all the children,
aged between two to ten, who presented with fever (axil-
lary temperature > 37.5°C) and a presumptive diagnosis
of mild malaria during an initial consultation. Each pro-
vider was given a chart showing the appropriate dosage by
weight and age, defined by the Senegalese National
Malaria Control Program (Table 1). This program recom-
mended that all children be prescribed a single dose of SP
(25 mg sulphadoxine/kg; 1.25 mg pyrimethamine/kg) on
day 0 (D0), and one daily dose of AQ for 3 days (D0 to
D2: 10 mg/kg/day). The program did not expect nurses to
supervise the first intake. Drugs were available at the
health centre pharmacy.
A thick blood film was used to measure the parasitaemia
at D0. This allowed a biological confirmation of the diag-
nosis and the inclusion of children in the effectiveness
study. Nurses did not know the results at the time of pre-
scription. No study team member was present at the
health center. Each evening, identification forms and
blood smears were collected from the nurses. Children
were recruited the day after the last treatment dose (D3),
Table 1: Age-specific dosing schedule for sulphadoxine-pyrimethamine (SP) and amodiaquine (AQ) in Senegal
SP tablets* AQ tablets**
Age group Weight Day 0 Day 0 Day 1 Day 2
2--11 months 5 - 10 kg 0.5 0.5 or 2 tsp 0.5 or 2 tsp 0.5 or 2 tsp
1--2 years 10.1 -14 kg 0.75 0.75 or 3 tsp 0.75 or 3 tsp 0.75 or 3 tsp
3- 5 years 14.1 - 20 kg 1 1 or 4 tsp 1 or 4 tsp 1 or 4 tsp
6-8 years 20,1 - 30 kg 1.5 1.5 1.5 1.5
9-11 years 30,1 - 40 kg 2 2 2 2
12-13 years 40,1 - 50 kg 2.5 2.5 2.5 2.5
> 14 years > 50 kg 3 3 3 3
* SP: 1 tablet contains 500 mg of sulphadoxine and 25 mg of pyrimethamine
** AQ: 1 tablet contains 153 mg of amodiaquine and 1 teaspoon (tsp = 5 ml) contains 50 mg of amodiaquine
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when mothers/guardians were visited at home where the
study design was explained and their written consent
obtained. Free and informed consent was sought from the
children's caregivers before administration of the ques-
tionnaires and blood samples. Apart from the study team,
no one was aware of this visit. Pharmacy registers were
checked regarding the dispensing of drugs to patients, the
quantity of drug dispensed and the date of drug purchase
to determine D3. The study was approved by the Senega-
lese ethical committee.
Measurement of compliance using self-reported data
The questionnaire was addressed to caregivers and accom-
panying adults the day following the end-of-treatment
intake (D3) or during the following three days in case of
absence (D4-D5). Questionnaires were translated into the
local languages; they were administered in the form of an
interview. Interviewers were trained during one week for
the questionnaire and a pre-test was done in villages out-
side the study area. The individual questionnaire included
nine sections with questions related to the following
issues: respondents' socio-economic and demographic
characteristics, history of febrile illness, consultation at
the health center, child health status between D0 and the
interview day, compliance with treatment, knowledge
about malaria, source of information and attitudes
towards health and drugs. If the caregiver was different
from the accompanying adult, he was asked the questions
concerning the health center and consultation. The last
section was addressed to children; they were asked about
the drugs (intake, taste) and about their disease and recov-
ery. Open questions were asked about treatment compli-
ance including dose, duration and frequency. Other
questions addressed vomiting and dose replacement. To
measure compliance, the caregiver's administration of the
drugs was compared with the nurse's prescription. Three
levels of compliance were defined. The first one based on
drug administration indicates whether there has been at
least one intake of each drug. Secondly, those who took
80% of the prescribed dose of each one of the two drugs
were considered as compliant [9]. The entire declared
drug intake was added up and compared with the total
dose prescribed by the nurse. Thirdly, strict full adherence
(SFA) described a patient as fully adherent to the prescrip-
tion, including dose, duration and frequency. Patients
were required to take the daily exact dose of AQ prescribed
for three days and the exact dose of SP prescribed on the
first day. The first level --at least one drug intake--was used
for comparison with the blood and urine assay results.
The families were re-interviewed the month following the
end of the survey, in case of discrepancies observed
between self-reported and urine assay results.
Biological assays
Biological assays were carried out among a subgroup of
children. Those who presented with a biologically-con-
firmed malaria attack (D0 parasitaemia > 2500/μL) and
who where included into the effectiveness study were
recruited. Urine and blood assays (taken from inside arm
at elbow) were performed to measure drug intake. Blood
samples were stored at -20°C.
An assay of sulphadoxine--standing for sulphadoxine/
pyrimethamine combination--was performed using a
colorimetric method for detecting sulphonamides in
urine. The method uses the color agent, p-dimethylami-
nocinnamaldehyde, and has a detection limit of about 1
μg/ml [10]. Blood samples (2 ml) were analysed to detect
the presence and concentration of mono-desethyl amodi-
aquine (MDA), sulphadoxine, pyrimethamine, and chlo-
roquine in order to assess a possible self-medication. A
High Performance Liquid Chromatography (HPLC)
method in the reversed-phase mode with an ultraviolet
diode array detection (λ = 343 nm for AQ and CQ and λ
= 270 nm for SP) was performed to measure molecular
compounds in blood. It was based on the method devel-
oped by Pussard and Verdier [11].
Results
Socio-demographic characteristics of children and 
compliance
The study was conducted in five health centers in which
289 children were recruited. One hundred and forty-five
children had laboratory-confirmed malaria (parasitaemia
> 2,500/μl) and 144 were diagnosed presumptively by the
nurses (117 were negative and 28 had a parasitaemia < =
2,500/μl). The median age of the recruited children was
5.4 years. The sex ratio (male/female) was 1.3. The mother
was the caregiver in 69.5% of the time followed by the
grandmother (13.2%), the father (7.6%) and others
(9.7%). Among all recruited children, 204 of them
(70.6%) were administered AQ in tablet form and 85
(29.4%) in syrup form. Two caregivers (0.7%) did not buy
AQ and six (2.1%) did not buy SP.
Among the 145 children presenting with malaria--vali-
dated by a biological test--some 138 (95.2%) venous
blood samples for an assay of amodiaquine and SP and
139 urine samples (95.9%) for an assay of sulphadoxine
were performed at D3. All caregivers of the 289 recruited
children were interviewed using a questionnaire between
D3 and D5.
Measurement of compliance
Self-reported data
Most patients (94.1%) took at least one dose of each of
the two drugs. Among the children, 64.7% were consid-
ered as compliant to the dose prescribed by the nurse, and
37.7% were fully compliant to the prescription of the two
medications. Compliance was higher for SP than for AQ
(Table 2). Strict full adherence to amodiaquine was higher
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among children who were administered tablets (45%)
than among those who took syrup (28.2%).
Blood and urine assays
Results obtained with HPLC indicate that a concentration
of the amodiaquine metabolite--mono-desethyl amodi-
aquine (MDA)--has been measured in blood for only
70.5% of cases. Regarding SP, 92.8% of patients had pos-
itive blood dosages of both sulphadoxine and pyrimeth-
amine that express a double confirmation of drug intake.
Some 84.2% of children had a positive urine test for sul-
fonamides (Table 3).
Comparison between results based on different methods
Sulphadoxine assays in blood and urine
There is good correlation between blood and urine dos-
ages for SP: for 91.4% of patients, identical results were
found using both techniques. Using the HPLC assay
method as the reference, no false positives were observed
and the rate of false negatives was 8.6% (12/139). The
mean concentration using HPLC was 25.3 μg/ml [9.4-
41.3] for patients with a negative urine test (22/139) and
74.8 μg/ml [66.2-79.5] for those with a positive urine test
(117/139) (p < 0.001) (Table 3).
Sulphadoxine assays in blood and self-reported data
There was a 90% agreement between data from question-
naires and results obtained by HPLC. Seven caregivers
reported having administered SP to their children while
dosages by HPLC were negative and seven others said they
did not give SP to their children while HPLC dosages were
positive--i.e. 5% of false positives and 5% of false nega-
tives (Table 3).
Blood dosages of AQ and self-reported data
The correspondence between blood dosages and ques-
tionnaires responses was 72.7%. Many patients had a neg-
ative dosage by HPLC--41 patients among 139, i.e. 29.5%.
Among these patients, only three reported not having
taken amodiaquine (Table 3). The mean duration
between the last intake and the sample was similar for
both groups--10.6 hours [8.9-12.5].
Reported intake and concentration in blood or urine
For SP, concentrations of sulphadoxine in blood and
urine were used and for amodiaquine, blood concentra-
tions of its metabolite--mono-desethylamodiaquine
(MDA). The results do not allow us to establish a relation-
ship between the quantity of medication intake (mg/kg)
and the molecule concentrations found in blood (Figure
1 and 2). Correlation was respectively 0.1606 and 0.1591
for S and P and 0.0704 for AQ; results were insignificant
(0.0628, 0.0654 and 0.4204).
Discussion
Amodiaquineassays in blood: encountered storage 
difficulties
For almost one third of children (29.5%), the blood con-
centration of MDA was nil, while their parents had
reported giving them amodiaquine. A low rate of positive
assays seems to be related to the conservation of the sam-
ple. The assays have been performed two years after the
collection. In this study, glass tubes were used, whereas
polypropylene tubes would probably have limited the
adsorption of the MDA molecule by the glass [12]. Given
the literature, this seems to be a potential argument. The
last hypothesis concerns the preservation of samples in
terms of their storage in a dark place to prevent photo-
degradation of the molecule and its metabolites [13], and
the temperature to preserve samples. In a recent study,
tubes of spiked blood containing AQ and MDA were kept
respectively at -20°C and -86°C for 148 days. Only 35%
of the initial quantity of AQ was found in the whole-
blood samples that were kept at -20°C, whereas 97% to
99% were measured in the whole-blood samples kept at -
86°C and in stored plasma kept at -20°C or -86°C [14].
SP assays in blood: a good correlation between results
Each blood sample was tested for both sulphadoxine and
pyrimethamine. Results were similar for all the subjects.
In addition, a good correlation with results based on self-
reported data was observed. The cases of discrepancies--
seven false negatives and seven false positives--were exam-
ined and are explained by the fact that families had diffi-
culties identifying the drugs once the blisters were cut and
put in a bag. The SP tablet--white and approximately the
size of an aspirin tablet--was identified as an aspirin tablet
and families reported having only taken an antipyretic.
Conversely, other families reported having given SP
though they only gave aspirin. The observed differences
seem to be explained more by a confusion between the
Table 2: Adherence indicators: results of self reported data
AQ SP Combination
Intake 285 (98.6%) 272 (94.1%) 272 (94.1%)
Adherent (with 80% threshold) 209 (72.3%) 245 (84.8%) 187 (64.7%)
Strict full adherent 114 (39.4%) 176 (60.9%) 109 (37.7%)
Intake: administration of the drug at least one time; Adherent (with 80% threshold): administration of 80% of the prescribed dose; Strict Full 
Adherence: administration exactly as prescribed by the nurse (dose, duration, frequency)
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drugs than by the respondent's desire to conceal informa-
tion.
Advantages and disadvantages of blood assays
Venous blood sampling has the disadvantage of being
invasive and often badly perceived by families, in particu-
lar when it concerns young children [15]. However, in the
study there were no refusals to perform blood tests, but
there were missing samples as a result of absence of chil-
dren at D3 and some failures due to the difficulty of some
samplings (4.8%). This success is the result of the estab-
lishment of a close relationship with the families and
community leaders. This method is also restrictive in
terms of time--time-length between medication intake
and blood sampling as well as between sampling and
freezing-- and sample preservation particularly in the field
where appropriate material conditions are not always
available. Moreover, the results show that blood assays
only give qualitative information on whether there has
been any drug intake. A strong variability of blood con-
centration whatever the intake has been observed [16].
This high inter-individual variability of MDA could be
attributed to the different rates of hepatic metabolism of
each individual. It appears in others surveys to have a
greater effect on MDA levels than the number of timing
doses [17,18]. Blood assays seem to have a limited role in
discussing drug intake after no intake or intake of one and
more doses [17].
Table 3: Comparison of results based on self-reported data and urine assays with blood assays
SP assays in blood
Positive Negative Total
Self-reported data/SP intake Positive 122 (87.8%) 7 (5%) 129 (92.8%)
Negative 7 (5%) 3 (2.2%) 10 (7.2%)
Total 129 (92.8%) 10 (7.2%) 139 (100%)
SP assays in urine Positive 117 (84.2%) 0 117 (84.2%)
Negative 12 (8.6%) 10 (7.2%) 22 (15.8%)
Total 129 (92.8%) 10 (7.2%) 139 (100%)
AQ assays in blood
Positive Negative Total
Self-reported data/AQ intake Positive 98 (70.5%) 38 (27.3%) 136 (97.8%)
Negative 0 3 (2.2%) 3 (2.2%)
Total 98 (70.5%) 41 (29.5%) 139 (100%)
Blood concentration of monodesethylamodiaquine by self-rep rted m dic intakeFigu e 1
Blood concentration of monodesethylamodiaquine 
by self-reported medication intake.
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SP assays: the advantages of urine over blood samples
Results from urine dosages of sulphadoxine correspond
with the blood dosage results. The sensitivity of this meas-
ure is 91% and the specificity is 100%. In his study, Mount
obtained a sensitivity of 94% and a specificity of 94%
while comparing the results from this method with those
using HPLC [10]. This method is particularly appealing
given the good sensitivity and specificity of the assays as
well as the simplicity of use and ease in sampling com-
pared to a venous blood sample. SP is currently no longer
or rarely used in artemisinin-based combination therapy.
Nevertheless, it is used in the form of intermittent preven-
tive treatment (IPT) for pregnant women for malaria che-
moprophylaxis. Urine samples are often collected among
pregnant women during prenatal care to measure albu-
min. This technique of urine assays could easily be imple-
mented, and used for studies on compliance and
effectiveness of this prophylaxis during uncontrolled
intakes. Results such as those obtained with blood assays
only provide a qualitative validation of the intake. In this
case, the purpose is not to collect individual data but to
have an interesting epidemiological tool to obtain public
health data on chemoprophylaxis among pregnant
women.
Validity of questionnaires
Self-reported data on medication intake are often contro-
versial. Self-reported data have the disadvantage of being
subject to the reliability of the respondent's self-reporting
of his or her behavior. There is also a potential recall bias,
inherent in all data collection subsequent to the events
[19,6]. In a study carried out in Malawi regarding a prior
treatment to the examination at the health centre, families
reported not having taken tablets, although he found sul-
phadoxine or chloroquine in the children's urine [7]. In
another study, conducted on compliance with chemo-
prophylaxis among pregnant women, the reported com-
pliance was much higher than the one observed by assays
[20]. In this case, it is mentioned that the bias stems from
the fact that subjects are prone to answer what is expected
of them [21]. Conversely, other studies demonstrate a
good reliability of results based on self-reporting. In a
study carried out in China, Qingjun found a 97% compli-
ance with a primaquine and chloroquine blister based on
self-reporting and on urine assay of phenobarbitol--added
as a drug marker [22]. In a study in Uganda [23], compli-
ance was measured by self-reporting, blister counts, and
plasma lumefantrine assay. Fogg found lower levels of
lumefantrine in plasma among non-adherent patients
than among adherent patients, although the results were
not statistically significant [23].
A good correlation was found between self-reported data
and SP assays by HPLC. These results validate the value
ascribed to self-reported data whenever patients did not
experience this as a means to check their behaviors [3].
The interviewer must establish a relationship with the
patient without expressing any judgment or attaching any
value to the respondent's answers [3]. A long and detailed
interview with the child's caregiver is needed to obtain
reliable data and reconstruct the drug-intake history. The
one-hour long interview may have appeared as a con-
straint for some families. However, there were no refusals.
The quality of the questioning is also essential. The ques-
tionnaire is a specific scientific tool for which the structure
and sequences of questions are capital. The quality of
results will depend on these components. Internal valida-
tion methods exist that use cross-questions to specifically
validate responses. The delay between the events and col-
lection of data is also a central element to limit recall
biases. The fact that interviews with the families were car-
ried out the days following the end of the treatment
restricted recall biases. Even under strict methodological
conditions, the collection of self-reported data in the field
is less constraining than biological assays. Questionnaires
were filled out between the third and fifth day after the
medical examination; this simplified the material organi-
zation of the study. Furthermore, self-reported data pro-
vided in-depth information on children's drug use in
terms of timing, amount, and duration. Another method
would not have provided such accuracy. These data have
also highlighted the patients' difficulties and behaviors
concerning drug intake and compliance with the treat-
ment, and allow us to better understand the factors poten-
tially involved [24].
Conclusion
Compliance is not only the measurement of medication
intake, but also concerns the intake timing, doses, and
treatment duration. All these dimensions can only be
assessed by the use of self-reported data or by the imple-
mentation of more expensive modern methods such as
electronic pill-boxes. This confirms the specific contribu-
tion of self-reported data to measure compliance. Blood
and urine drug dosages provide qualitative results useful
to confirm drug intake. Urine assays for SP could be useful
to obtain public health data, like for chemoprophylaxis
among pregnant women. In malaria-endemic countries
self-reported data appears under rigorous methodology
conditions --e.g. using confirmation by hospital prescrip-
tion records-- as the easiest method to comprehend the
patients' behavior and drug use in order to develop tools
to improve compliance with treatment regimens.
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